-
Posted by
Two Blokes Apr 28 -
Filed in
Stock
-
4 views
Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S. tariffs.
